Genex Pharmaceutical, Inc. (GENX)

Genex Pharmaceutical, Inc. (GENX) — VMCI valuation read

Genex Pharmaceutical, Inc. (GENX) carries a VMCI composite of 65/100, 15 points above the Healthcare sector median of 50. Among mid-cap names, that gap places GENX in the top third on the five-pillar weighting (Value 35%, Quality 30%, Integrity 15%, Growth 12%, Risk 8%).

The GENX insider tape has been silent for the past 30 days on Form 4. Where executives neither buy nor sell, the bull and bear cases lean harder on filings cadence and the next earnings line.

**Investor frame.** Value reads GENX trades at 24.0x earnings, 33% above the Healthcare median of 18.0x, which compresses or extends through the 11.0x EV/EBITDA versus a Healthcare 12.0x. Quality: ROIC of 10.0% sits 0.0pp above the Healthcare median (10.0%). Risk: net debt to EBITDA of -1.6x leaves covenant headroom, the line to track on Genex Pharmaceutical, Inc.'s next 10-Q.

GENX held flat 0.0% over the trailing 7 days, with a -16.0% read on a 30-day basis.